文献速递功能神经外科

第二阶段DBS无需等待:同日低幅激活在单侧为主队列中的安全性

Stage 2 DBS without the wait: safety of same-day low-amplitude activation in a predominantly unilateral cohort.
PubMed 文献 · J Neurosurg · 2026-10-30

该单中心回顾性研究纳入2019–2024年561例第二阶段DBS手术,比较同日低幅激活与历史延迟激活方案。倾向评分校正后,同日激活达到非劣效标准,未校正不良事件率更低(3.8% vs 20.5%),且程控稳定性更优。结论提示同日低幅激活至少与延迟激活同样安全,但未确立立即全治疗性激活的安全性。

要点

  • 同日低幅激活在第二阶段DBS后6个月复合不良事件率上非劣效于延迟激活。
  • 同日激活组未校正不良事件率3.8%,延迟组20.5%,点估计利于同日激活。
  • 同日激活组6个月程控保留率78.5%,高于延迟组的54.9%。

核心结论

  • 同日低幅激活在第二阶段DBS后至少与延迟激活同样安全,并伴随更少的早期不良事件和更持久的程控。
  • 该方案缩短了早期无刺激间隔,可在采用单侧植入的项目中实施。
  • 研究未确立立即全治疗性激活的安全性,也未比较运动疗效。

研究设计与样本

  • 回顾性单中心研究,采用倾向评分校正的连续第二阶段DBS手术队列,2019–2024年共561例(延迟组273例,同日激活组288例),均随访≥6个月。
  • 第一阶段为颅内电极植入,第二阶段为脉冲发生器及延伸导线植入。
  • 同日激活组采用保守电流上限、固定触点选择和患者程控仪护栏。

主要发现

  • 同日激活组第一阶段至第二阶段中位间隔3.0天(Q1-Q3:2.5-3.5天),第一阶段至激活中位间隔亦为3.0天(2.5-3.5天)。
  • 延迟组第一阶段至第二阶段中位间隔4.0天(2-9天),第一阶段至激活中位间隔18.0天(13-29天,IQR 16天)。
  • 未校正不良事件率:同日激活组3.8%(11/288),延迟组20.5%(56/273),风险差-16.7%(95%CI -22.0至-11.4)。
  • 首次完整程控后6个月,初始设置保留率同日激活组78.5%,延迟组54.9%;首次更改时间有利于同日激活(延迟vs同日HR 2.28,95%CI 1.89-2.73)。
  • Kaplan-Meier曲线显示差异持续至36个月;探索性分析中双侧病例短期言语和意识状态改变事件更高,感染、出血、侵蚀或电极移位无差异。

关键数值与推荐

  • 主要终点为第二阶段后6个月复合不良事件率(手术、设备或刺激相关)。
  • 倾向校正分析中,同日激活满足非劣效标准(风险差异上限95%CI < 5%)。
  • 无设备相关死亡。

临床怎么用

  • 对于以单侧植入为主的DBS项目,可考虑在第二阶段手术当日实施低幅激活,以缩短无刺激等待期。
  • 实施时需采用保守电流上限、固定触点选择和程控护栏等标准化方案。
  • 不应将结果外推至立即全治疗性激活或用于比较运动疗效。

局限性

  • 回顾性单中心设计,存在历史对照和选择偏倚可能。
  • 未确立立即全治疗性激活的安全性,也未评估运动疗效。
  • 需前瞻性多中心研究确认持久性、患者报告结局和资源使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Postoperative deep brain stimulation (DBS) programming schedules vary across institutions. At some centers, patients may experience an additional post-stage 2 interval without stimulation before the first outpatient programming visit. In the present study, authors evaluated the safety and operational feasibility of a standardized same-day low-amplitude activation protocol on the day of stage 2 DBS surgery compared with a historical delayed-programming pathway at their center. METHODS: A retrospective single-center study was conducted using a propensity score-adjusted cohort of consecutive stage 2 DBS procedures performed between 2019 and 2024. Stage 1 denoted intracranial lead implantation, whereas stage 2 signified implantable pulse generator and extension wire insertion. Cases were divided into 2 cohorts, a historical delayed-activation group and an immediate-activation group (same day, conservative current ceilings, fixed contact selection, patient-programmer guardrails). The primary endpoint was the composite 6-month post-stage 2 adverse events rate (surgical, device, or stimulation related). RESULTS: The study included 561 consecutive procedures (273 delayed, 288 immediate); all had ≥ 6 months of follow-up. In the immediate cohort, the median interval from stage 1 to 2 was 3.0 days (Q1-Q3: 2.5-3.5 days), and the median interval from stage 1 to activation was also 3.0 days (2.5-3.5 days) because of same-day activation. In the delayed cohort, the median interval from stage 1 to 2 was 4.0 days (2-9 days) while the median from stage 1 to activation was 18.0 days (13-29, IQR 16 days). In propensity-adjusted analyses, immediate activation met the noninferiority criterion (upper 95% CI for risk difference < 5%); point estimates favored immediate activation. Unadjusted adverse event rates were 3.8% (11/288) for the immediate cohort versus 20.5% (56/273) for the delayed cohort (risk difference -16.7%, 95% CI -22.0 to -11.4). No device-related deaths occurred. Program stability was greater with immediate activation: at 6 months after the first full programming visit, retention of the settings established at that initial visit was 78.5% in the immediate cohort versus 54.9% in the delayed cohort, and the time to first change favored immediate activation (HR 2.28, 95% CI 1.89-2.73 for delayed vs immediate). Kaplan-Meier curves showed separation persisting to 36 months. In exploratory analyses, bilateral cases had higher short-term speech and altered mental status events, without differences in infection, hemorrhage, erosion, or lead migration. CONCLUSIONS: In a large consecutive, propensity score-adjusted cohort, same-day low-amplitude activation after stage 2 was at least as safe as delayed activation, coinciding with fewer early post-stage 2 adverse events and more durable programming. This protocol shortens the early no-stimulation gap and can be implemented in programs employing unilateral implantation. However, these findings do not establish the safety of immediate full therapeutic activation or comparative motor efficacy. Prospective multicenter evaluations should confirm durability, patient-reported outcomes, and resource use.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Uppalapati SC, Qushair FA, Bentley JN, et al. Stage 2 DBS without the wait: safety of same-day low-amplitude activation in a predominantly unilateral cohort. J Neurosurg. 2026. PMID: 42962237. doi:10.3171/2026.5.JNS252976

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。